Goldman Sachs’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.46M Buy
684,418
+359,091
+110% +$854K ﹤0.01% 4806
2025
Q4
$791K Sell
325,327
-123,691
-28% -$438K ﹤0.01% 5295
2025
Q3
$1.7M Buy
449,018
+98,374
+28% +$288K ﹤0.01% 4616
2025
Q2
$870K Sell
350,644
-128,743
-27% -$248K ﹤0.01% 4801
2025
Q1
$743K Sell
479,387
-4,449
-0.9% -$9.33K ﹤0.01% 4921
2024
Q4
$1.04M Buy
483,836
+202,820
+72% +$581K ﹤0.01% 4802
2024
Q3
$1.22M Buy
281,016
+217,896
+345% +$1.19M ﹤0.01% 4503
2024
Q2
$294K Sell
63,120
-270,128
-81% -$1.45M ﹤0.01% 5117
2024
Q1
$1.69M Buy
333,248
+287,263
+625% +$1.16M ﹤0.01% 3983
2023
Q4
$129K Buy
+45,985
New +$108K ﹤0.01% 5251
2023
Q2
Sell
-36,679
Closed -$69.3K 5753
2023
Q1
$69.3K Sell
36,679
-327
-0.9% -$751 ﹤0.01% 5507
2022
Q4
$66.6K Sell
37,006
-17,972
-33% -$32.4K ﹤0.01% 5560
2022
Q3
$93K Sell
54,978
-47,148
-46% -$145K ﹤0.01% 5704
2022
Q2
$251K Sell
102,126
-78,971
-44% -$184K ﹤0.01% 5519
2022
Q1
$502K Buy
181,097
+48,941
+37% +$179K ﹤0.01% 5315
2021
Q4
$704K Buy
132,156
+6,050
+5% +$42.3K ﹤0.01% 5116
2021
Q3
$1.07M Sell
126,106
-67,356
-35% -$665K ﹤0.01% 4692
2021
Q2
$2.36M Buy
193,462
+108,934
+129% +$2.15M ﹤0.01% 4046
2021
Q1
$2.05M Buy
84,528
+12,272
+17% +$331K ﹤0.01% 3959
2020
Q4
$2.32M Buy
72,256
+64,384
+818% +$2.12M ﹤0.01% 3621
2020
Q3
$238K Sell
7,872
-9,145
-54% -$278K ﹤0.01% 4847
2020
Q2
$718K Sell
17,017
-73,020
-81% -$2.69M ﹤0.01% 4167
2020
Q1
$2.25M Buy
+90,037
New +$2.74M ﹤0.01% 3219

Other funds holding BDTX

Goldman Sachs's BDTX Position: Q1 2026 in Review

Goldman Sachs increased its Black Diamond Therapeutics (BDTX) stake by 110% in Q1 2026, buying an estimated $854K and bringing the position to 684,418 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #4806.

Goldman Sachs first reported a position in BDTX in Q1 2020 and has held it in 23 quarters since. The position peaked at $2.36M in Q2 2021. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Goldman Sachs held 684,418 shares of Black Diamond Therapeutics worth $1.46M as of Q1 2026.
  • Goldman Sachs bought 359,091 Black Diamond Therapeutics shares in Q1 2026, an estimated $854K.
  • Black Diamond Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4806 holding.
  • Goldman Sachs first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Black Diamond Therapeutics position peaked at $2.36M in Q2 2021.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.